U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22N2S
Molecular Weight 298.446
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Vortioxetine

SMILES

CC1=CC(C)=C(SC2=CC=CC=C2N3CCNCC3)C=C1

InChI

InChIKey=YQNWZWMKLDQSAC-UHFFFAOYSA-N
InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C18H22N2S
Molecular Weight 298.446
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=15341484; http://www.ncbi.nlm.nih.gov/pubmed/?term=21486038

Vortioxetine is an antidepressant for the treatment of major depressive disorder. Vortioxetine’s mechanism of action is not fully understood. Vortioxetine binds with high affinity to the serotonin transporter and its antidepressant actions are believed to be secondary to enhancing serotonin in the central nervous system through inhibition of reuptake. Vortioxetine also displays binding affinities to other serotonin (5-HT) receptors, including 5-HT3, 5-HT1A, and 5-HT7. Due to multimodal neurotransmitter enhancer profile, it has been suggested that it might need lesser receptor occupancy rate for clinical trials than other selective serotonin reuptake inhibitors and selective norepinephrine reuptake inhibitors. Since vortioxetine is an agonist and antagonist of multiple serotonin receptors, potential interactions may occur with other medications that alter the serotonergic pathways. There is an increased risk of serotonin syndrome when vortioxetine is used in combination with other serotonergic agents.

CNS Activity

CNS Active
4002
Curator's Comment: Vortioxetine is a SSRI that binds to the presynaptic serotonin reuptake site, increasing the level of serotonin (5-HT) in the neuronal synapse, as well as selectively binding to a variety of other serotonin receptors, thus enhancing CNS serotonergic activity.

Originator

Lundbeck
46
Curator's Comment: Trintellix (vortioxetine) was discovered by Lundbeck researchers in Copenhagen, Denmark. The clinical trial program in the United States was conducted jointly by Lundbeck and Takeda, and Takeda holds the new drug application for the U.S. market. Trintellix is a trademark of H. Lundbeck A/S and used under license by Takeda Pharmaceuticals America, Inc.

Approval Year

2013
589
Targets

Targets

Primary TargetPharmacologyConditionPotency
5-hydroxytryptamine receptor 3A
7
Target ID: P46098
Gene ID: 3359.0
Gene Symbol: HTR3A
Target Organism: Homo sapiens (Human)
Antagonist
2849
 3.7 nM [Ki]
5-hydroxytryptamine receptor 7
16
Target ID: P34969
Gene ID: 3363.0
Gene Symbol: HTR7
Target Organism: Homo sapiens (Human)
Antagonist
2849
 19.0 nM [Ki]
5-hydroxytryptamine receptor 1D
18
Target ID: P28221
Gene ID: 3352.0
Gene Symbol: HTR1D
Target Organism: Homo sapiens (Human)
Antagonist
2849
 54.0 nM [Ki]
5-hydroxytryptamine receptor 1B
22
Target ID: P28222
Gene ID: 3351.0
Gene Symbol: HTR1B
Target Organism: Homo sapiens (Human)
Antagonist
2849
 33.0 nM [Ki]
5-hydroxytryptamine receptor 1A
58
Target ID: P08908
Gene ID: 3350.0
Gene Symbol: HTR1A
Target Organism: Homo sapiens (Human)
Antagonist
2849
 15.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
BRINTELLIX

Approved Use

Indicated for the treatment of major depressive disorder (MDD).

Launch Date

2013
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33.03 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.11 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.654 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: healthy
age:
sex:
food status:
0.029 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA39835 plasma
Homo sapiens
population: healthy
age:
sex:
food status:
2.078 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.374 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
0.008 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA39835 plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
1.67 ng/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
4.6 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.92 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
33 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204447s013lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
645.78 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
645.51 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
88.614 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: healthy
age:
sex:
food status:
122.899 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.143 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA39835 plasma
Homo sapiens
population: healthy
age:
sex:
food status:
166.955 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
187.202 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: healthy
age:
sex:
food status:
71.942 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
124.708 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA34443 plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
0.078 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
LU-AA39835 plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
188.663 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
288.053 ng*h/mL
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT02170220
5 mg single, oral
dose: 5 mg
route of administration: oral
experiment type: single
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
273.42 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
344 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
64.23 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.28 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
60.62 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
58.84 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
66 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204447s013lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1%
REVIEW
https://pubmed.ncbi.nlm.nih.gov/29189941/
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204447s013lbl.pdf
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VORTIOXETINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg 1 times / day steady, oral
Highest studied dose
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
healthy, 24 years(range: 18–53) years.
Health Status: healthy
Age Group: 24 years(range: 18–53) years.
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
75 mg single, oral
Highest studied dose
Dose: 75 mg
Route: oral
Route: single
Dose: 75 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
healthy, 24 years(range: 18–53) years.
Health Status: healthy
Age Group: 24 years(range: 18–53) years.
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
9 mg single, intravenous
Dose: 9 mg
Route: intravenous
Route: single
Dose: 9 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
healthy, 24 years(range: 18–53) years.
Health Status: healthy
Age Group: 24 years(range: 18–53) years.
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
Sources:
https://pubmed.ncbi.nlm.nih.gov/22448783
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29923970
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/29923970
Other AEs: Suicide attempt...
Other AEs:
Suicide attempt
Sources:
https://pubmed.ncbi.nlm.nih.gov/29923970
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
Disc. AE: Nausea...
Other AEs: Suicidal ideation, Suicidal behavior...
AEs leading to
discontinuation/dose reduction:
Nausea
Other AEs:
Suicidal ideation
Suicidal behavior
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
Disc. AE: Reaction skin, Vomiting...
AEs leading to
discontinuation/dose reduction:
Reaction skin
Vomiting
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Suicide attempt
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/29923970
unhealthy, 50 years
Health Status: unhealthy
Age Group: 50 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/29923970
Suicidal behavior
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
Suicidal ideation
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
Nausea Disc. AE
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf
Reaction skin Disc. AE
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
Vomiting Disc. AE
20 mg 1 times / day steady, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1193

inducer
440

inhibitor
2438
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741

CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2E1
1060

CYP3A4/5
296

CYP2C8
1057

BCRP
910

BSEP
550

MATE1
415

MATE2
267

OAT1
725

OAT3
747

OATP1B1
1079

OATP1B3
961

OCT1
620

OCT2
779
P-gp
2052

CYP3A4/5
91

CYP2C19
1119

CYP2A6
626

CYP2C8
810

CYP2B6
776
CYP1A2
832

CYP2A6
86

CYP2B6
669

CYP2C8
198

CYP2C19
329

CYP3A4/5
133
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 moderate [IC50 4.4 uM]
no (co-administration study)
Comment: no dose adjustment needed for vortioxetine coadministration with digoxin
Page: 27.0
CYP2A6
911
 no [IC50 >34 uM]
CYP2B6
1160
 no [IC50 >34 uM]
CYP2D6
2546
 no [IC50 >34 uM]
CYP2E1
1146
 no [IC50 >34 uM]
CYP3A4/5
357
 no [IC50 >34 uM]
BCRP
985
 no
BSEP
554
 no
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2A6
911
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP3A4/5
357
 no
MATE1
416
 no
MATE2
267
 no
OAT1
730
 no
OAT3
749
 no
OATP1B1
1095
 no
OATP1B3
970
 no
OCT1
656
 no
OCT2
782
 no
CYP2C9
2497
 yes [Ki 15 uM]
CYP2C8
1117
 yes [Ki 9.34 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1388
 major
likely (co-administration study)
Comment: dose decrease may be needed with CYP2D6 inhibitor such as bupropion, dose should be increased by 3 fold when administered with strong CYP inducer such as rifampacin
Page: 45, 47, 48, 56
P-gp
2052
 no
CYP2A6
626
 yes
CYP2C8
810
 yes
CYP2B6
776
 yes
unlikely (co-administration study)
Comment: no dose adjustment need with CYP2B6 substrate e.g. bupropion
Page: 48, 56, 80
CYP2C19
1119
 yes
unlikely (co-administration study)
Comment: no dose adjustment need with CYP2C19 substrate e.g. diazepam
Page: 48, 56, 80
CYP2C9
1193
 yes
unlikely (co-administration study)
Comment: no dose adjustment need with CYP2C9 substrate e.g. S-warfarin
Page: 48, 56, 80
CYP3A4/5
91
 yes
unlikely (co-administration study)
Comment: no dose adjustment need with CYP3A substrate e.g. midazolam
Page: 48, 56, 80
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
NO15845
https://www.001chemical.com/chem/508233-74-7
AA Blocks
AA00DB50
https://www.aablocks.com/goods/Goods/detail?id=AA00DB50
Aaron Chemicals
AR00DBWS
http://www.aaronchem.com/508233-74-7
abcr GmbH
AB459995
http://www.abcr.de/shop/en/AB459995
AbMole Bioscience
M6058
http://www.abmole.com/products/vortioxetine.html
Acadechem
ACDS-056587
http://www.acadechemical.com/product/131286
Achemo Scientific Limited
AC-78836
http://www.achemo.com/search/?Keyword= 508233-74-7
Achemtek
0102-013931
http://www.achemtek.com/508233-74-7
Acorn PharmaTech
ACN-036290
http://www.acornpharmatech.com/
AEchem Scientific Corp., USA
AE1-013736
http://www.aechemsc.com/info_products/AE1-013736.php
AK Scientific, Inc. (AKSCI)
7034AB
http://www.aksci.com/item_detail.php?cat=7034AB
Alsachim
3603
http://www.alsachim.com/product-C4887-glo.bal-view.html
Ambinter
Amb21926577
http://www.ambinter.com/reference/21926577
Angel Pharmatech
AG-26242
http://www.angelpharmatech.com/508233-74-7.html
Ansion Pharma
508233-74-7
http://www.ansionpharma.com/English/Product/1870421349.html
ApexBio Technology
A3926
http://www.apexbt.com/vortioxetine.html
Ark Pharm
AK110506
http://www.arkpharminc.com/products/508233-74-7.html
Ark Pharma Scientific Limited
H-009279
http://www.arkpharmtech.com/product/14334.html
Aurora Fine Chemicals LLC
A13.110.975
http://online.aurorafinechemicals.com/info?ID=A13.110.975
Aurum Pharmatech LLC
W-5909
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5909
AvaChem Scientific
3380
http://www.avachem.com/productSearch.asp?3380
BioChemPartner
BCP05996
http://www.biochempartner.com/508233-74-7-BCP05996
BioCrick
BCC2046
http://www.biocrick.com/Vortioxetine-BCC2046.html
Chem Scene
CS-1471
http://www.chemscene.com/508233-74-7.html
Chemspace
CSSB00020618850
https://chem-space.com/CSSB00020618850
DC Chemicals
DC8613
http://www.dcchemicals.com/product_show-Vortioxetine_Lu_AA21004_.html
Debye Scientific
DA-42264
http://www.debyesci.com/cas_508233-74-7.html
eNovation Chemicals
D541250
http://www.enovationchem.com/productDetails.asp?productID=D541250
Finetech
FT-0686961
http://www.finetechnology-ind.com/prod/detail/pub/508233-74-7.html
Fragmenta
PIP107
http://www.fragmenta.com/productDetails.asp?cellC=++style%3D%27background%3A%23E8F8FF%3B+color%3A%23fff%3B%27+&productID=PIP107
Hairui
HR118576
http://www.hairuichem.com/en/product/508233-74-7.html
Hefei Hirisun Pharmatech Co., Ltd
HR010072
http://www.hirisunpharm.com/508233-74-7.html
iChemical
EBD555355
http://www.ichemical.com/products/508233-74-7.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network
LN00201852
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00201852
LGC Standards
LGCFOR3264.00
https://www.lgcstandards.com/US/en/p/LGCFOR3264.00
LGC Standards
MM3264.00
https://www.lgcstandards.com/US/en/p/MM3264.00
Matrix Scientific
98153
https://www.matrixscientific.com/098153.html
MedChem Express
HY-15414
https://www.medchemexpress.com/Vortioxetine.html
Molcore
CS15845
https://www.molcore.com/product/508233-74-7
Sinfoo Biotech
S040930
http://www.sinfoobiotech.com/product/1044328
Smolecule
S546869
http://www.smolecule.com/products/s546869
Specs
AR-270/43507985
http://www.specs.net/enter.php?specsid=AR-270/43507985
Synblock Inc
SB16506
http://www.synblock.com/product/508233-74-7.html
THE BioTek
bt-286496
https://www.thebiotek.com/product/inhibitors/bt-286496
THE BioTek
bt-464311
https://www.thebiotek.com/product/others/bt-464311
Vitas-M Laboratory
STL483777
http://www.request.vitasmlab.com/index.php?option=com_search_stk&Itemid=22&stk=STL483777&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
PubMed

PubMed

TitleDatePubMed
Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
2011-05-12
Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
2004-09-09
Patents

Patents

08598348
5
08664225
5
08722684
5
20050014740
7
20060084662
7
20060089368
7
20070060574
7
20100297240
5
20110009422
5
20110009423
5
JP2010090165A
5
JP2013536206A
5
JP5371790B2
5

Sample Use Guides

In Vivo Use Guide
The recommended starting dose is 10 mg administered orally once daily without regard to meals. The dose should then be increased to 20 mg/day, as tolerated. Consider 5 mg/day for patients who do not tolerate higher doses. TRINTELLIX can be discontinued abruptly. However, it is recommended that doses of 15 mg/day or 20 mg/day be reduced to 10 mg/day for one week prior to full discontinuation if possible. The maximum recommended dose is 10 mg/day in known CYP2D6 poor metabolizers.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:28:51 GMT 2025
Edited
by admin
on Wed Apr 02 09:28:51 GMT 2025
Record UNII
3O2K1S3WQV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
vortioxetine [INN]
Preferred Name English
Vortioxetine
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
LU-AA21004
Code English
LU AA21004
Code English
VORTIOXETINE [USAN]
Common Name English
PIPERAZINE, 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)-
Systematic Name English
VORTIOXETINE [MI]
Common Name English
1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine
Systematic Name English
Vortioxetine [WHO-DD]
Common Name English
LUAA21004
Code English
VORTIOXETINE [VANDF]
Common Name English
Classification Tree Code System Code
WHO-ATC N06AX26
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
WHO-VATC QN06AX26
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
NCI_THESAURUS C265
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
Code System Code Type Description
SMS_ID
100000139835
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID80965062
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
DAILYMED
3O2K1S3WQV
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
DRUG CENTRAL
4806
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
FDA UNII
3O2K1S3WQV
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
RXCUI
1455099
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY RxNorm
HSDB
8250
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
EVMPD
SUB88928
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
LACTMED
Vortioxetine
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
NCI_THESAURUS
C152917
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
INN
9279
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
MERCK INDEX
m11708
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
CAS
508233-74-7
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104993
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
IUPHAR
7351
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
DRUG BANK
DB09068
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
WIKIPEDIA
VORTIOXETINE
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
CHEBI
76016
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
PUBCHEM
9966051
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
USAN
WW-43
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
MESH
C557874
Created by admin on Wed Apr 02 09:28:51 GMT 2025 , Edited by admin on Wed Apr 02 09:28:51 GMT 2025
PRIMARY
Related Record Type Details
Structure of Vortioxetine hydrobromide
SALT/SOLVATE -> PARENT
SODIUM-DEPENDENT SEROTONIN TRANSPORTER
TARGET -> INHIBITOR
BINDING
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 7
TARGET -> INHIBITOR
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
IC50
BETA-1 ADRENERGIC RECEPTOR
BINDER->LIGAND
Ki
SODIUM-DEPENDENT DOPAMINE TRANSPORTER
OFF TARGET->NON-INHIBITOR
BINDING
Ki
SODIUM-DEPENDENT NORADRENALINE TRANSPORTER
TARGET -> INHIBITOR
Ki
5-HYDROXYTRYPTAMINE RECEPTOR 3A
TARGET -> INHIBITOR
Ki
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
MAJOR
5-HYDROXYTRYPTAMINE RECEPTOR 1A
TARGET -> AGONIST
Ki
Structure of Vortioxetine hydrochloride
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
IC50
5-HYDROXYTRYPTAMINE RECEPTOR 1B
TARGET->PARTIAL AGONIST
Emax=55%
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
BETA-1 ADRENERGIC RECEPTOR
TARGET -> AGONIST
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 4-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL)-1-PIPERAZINYL-, METHYL ESTER
METABOLITE INACTIVE -> PARENT
UGT ENZYME NOT GIVEN
MAJOR
PLASMA
Structure of LU-AA34443
METABOLITE INACTIVE -> PARENT
AT 4 HOURS; ALCOHOL DEHYDROGENASE & ALDEHYDE DEHYDROGENASE ALSO INVOLVED IN METABOLISM
MAJOR
PLASMA
Structure of LU-AA39835
METABOLITE -> PARENT
Major Enzyme for this transformation
MINOR
PLASMA
Structure of LU-AA39835
METABOLITE -> PARENT
Minor Enzyme for this transformation
MINOR
PLASMA
Structure of LU-AA34443
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA
Structure of Vortioxetine sulfoxide
METABOLITE -> PARENT
MINOR
Structure of LU-AA34443
METABOLITE INACTIVE -> PARENT
OTHER METABOLITES INCLUDED
MAJOR
URINE
Structure of LU-AA34443
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL
Related Record Type Details
Structure of Vortioxetine
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966